Objective: The main objective is to identify potential biomarker panels that may represent disease onset, progression, and risk factors for Parkinson’s disease (PD).

Background: PD is caused by the degeneration of dopaminergic neurons, leading to reduced dopamine levels and a wide range of motor and non-motor disorders contributing to disability and death. Unfortunately, there are no specific laboratory tests available for the early diagnosis of PD, and the cure is on hold. Given the heterogeneity of PD and overlapping symptoms with other disorders, one biomarker may not be sufficient for accurate diagnosis.

Method: A systematic review of potential biomarkers for PD was conducted, including neuroimaging, oxidative stress, neuroprotection, and inflammation biomarkers from various sources of brain tissue, cerebrospinal fluid, blood, urine, and saliva. Recent advancements in alpha-synuclein seed amplification testing and multi-omics analysis in exosomes were also investigated.

Results: Dopamine transporter imaging test may be useful in diagnosis mostly limited by its availability, sensitivity, and resolution. Recent advances in testing, particularly those involving alpha-synuclein seed amplification, have shown promise. Given the heterogeneity of PD and overlapping symptoms with other disorders, one biomarker may not be sufficient for accurate diagnosis. Instead, a biomarker panel potentially incorporating multi-omics approaches will be needed. This panel should integrate various biomarkers derived from neuroimaging, oxidative stress, neuroprotection, and inflammation tested from brain tissue, CSF, blood, urine, and saliva. Additionally, exploring multi-omics analysis in exosomes could be beneficial, as exosomes protect their cargo from extracellular degradation and play a role in paracrine signaling that may contribute to disease progression.

Conclusion: Our review discusses all potential biomarkers currently available for PD and highlights recent developments in this field. A specific biomarker panel representing disease onset, progression, and risk factors for PD is essential. A biomarker panel potentially incorporating multi-omics approaches will need to be identified to integrate various biomarkers derived from neuroimaging, oxidative stress, neuroprotection, and inflammation.

« Back to 2025 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/biomarker-panels-for-parkinsons-disease-using-multi-omics-approach-recent-developments-and-future-directions/